Tislelizumab - CAS 1858168-59-8

Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

PD-1/PD-L1

Cell Cycle/Checkpoint, Apoptosis, Immunology/Inflammation

1858101

0.9507

-20°C

Ice Packs

Inhibitory Antibodies